Atorvastatin Trial in Moderate-to-Severe Thyroid Eye Disease Shows Potential for Enhanced Efficacy
The clinical trial, sponsored by Banu Aji Dibyasakti, is investigating the efficacy of atorvastatin at a dosage of 20 mg daily, administered alongside a standard 12-week course of intravenous methylprednisolone, in adults with active, moderate-to-severe Graves' orbitopathy.